Medicines Position Statements – NEL NEL Branded generics LPP and London Diabetes Network joint statement: Access to continuous glucose monitors for adults living with type 2 diabetes in London IQoro® position statement for hiatus hernia and reflux, stroke-related dysphagia and other indications (NEL)_02.2024 Position statement on generic and brand prescribing (NEL) Preferred DOAC prescribing position statement (NEL)_11.25 Initiation of statins for primary prevention of cardiovascular disease in patients with Liver disease NEL Preferred SGLT2i for Type 2 Diabetes, Heart Failure and Chronic Kidney Disease Position Statement Items which should not be routinely prescribed in primary care in North East London Items which should not be routinely prescribed in primary care in North East London Bath and Shower Preparations PIL Dosulepin PIL Doxazosin PIL Herbal Treatments PIL Immediate Release Fentanyl PIL Lidocaine Plasters PIL Liothyronine PIL Needles PIL Omega-3 Fatty Acid Compounds PIL Oxycodone and Naloxone Combination Products PIL Rubefacients PIL Trimipramine PIL